Abstract：
Impairments in lumbopelvic sensorimotor control (SMC) are thought to be one of the underlying mechanisms for the recurrence and persistence of low back pain (LBP). As such, lumbopelvic SMC tests are frequently included in the clinical examination of patients with LBP.
To evaluate convergent and known-groups validity of clinically assessed lumbopelvic SMC tests in patients with LBP according to COSMIN guidelines.
Systematic review METHODS: Five electronic databases were searched until December 2023. Studies examining convergent or known-groups validity of lumbopelvic SMC tests assessed via inspection or palpation in patients with LBP were included. Known-groups validity had to be assessed between patients with LBP and pain-free persons. Two independent researchers appraised risk of bias and quality of evidence (QoE) using the COSMIN Risk of Bias checklist and modified GRADE approach, respectively. Results for known-groups validity were reported separately for single tests and test-clusters.
Twelve studies (946 participants) were included. Three studies investigated convergent validity of three single tests. Regarding known-groups validity, six studies evaluated six single tests and four studies investigated two test-clusters. For only one test, both convergent and known-groups were assessed. The QoE for tests showing sufficient convergent or known-groups validity was (very) low, whereas QoE was moderate for single tests or test-clusters with insufficient known-groups validity.
All clinically assessed lumbopelvic SMC tests with sufficient convergent or known-groups validity had (very) low QoE. Therefore, test outcomes should be interpreted cautiously and strong reliance on these outcomes for clinical decision-making can currently not be recommended.
To evaluate convergent and known-groups validity of clinically assessed lumbopelvic SMC tests in patients with LBP according to COSMIN guidelines.
Systematic review METHODS: Five electronic databases were searched until December 2023. Studies examining convergent or known-groups validity of lumbopelvic SMC tests assessed via inspection or palpation in patients with LBP were included. Known-groups validity had to be assessed between patients with LBP and pain-free persons. Two independent researchers appraised risk of bias and quality of evidence (QoE) using the COSMIN Risk of Bias checklist and modified GRADE approach, respectively. Results for known-groups validity were reported separately for single tests and test-clusters.
Twelve studies (946 participants) were included. Three studies investigated convergent validity of three single tests. Regarding known-groups validity, six studies evaluated six single tests and four studies investigated two test-clusters. For only one test, both convergent and known-groups were assessed. The QoE for tests showing sufficient convergent or known-groups validity was (very) low, whereas QoE was moderate for single tests or test-clusters with insufficient known-groups validity.
All clinically assessed lumbopelvic SMC tests with sufficient convergent or known-groups validity had (very) low QoE. Therefore, test outcomes should be interpreted cautiously and strong reliance on these outcomes for clinical decision-making can currently not be recommended.
摘要：
背景：腰骨盆感觉运动控制（SMC）受损被认为是下腰痛（LBP）复发和持续的潜在机制之一。因此，LBP患者的临床检查中经常包括腰盆腔SMC测试。
目的：根据COSMIN指南，评估LBP患者临床评估的LumbopelvicSMC测试的收敛和已知组有效性。
方法：系统评价方法：搜索了5个电子数据库，直到2023年12月。包括通过检查或触诊评估的LBP患者腰骨盆SMC测试的收敛或已知组有效性的研究。必须在LBP患者和无痛人群之间评估已知组的有效性。两名独立研究人员使用COSMIN偏见风险清单和修改后的分级方法评估了偏见和证据质量（QoE）的风险。分别。对于单个测试和测试集群，分别报告了已知组有效性的结果。
结果：纳入12项研究（946名参与者）。三项研究调查了三个单一测试的收敛效度。关于已知群体的有效性，6项研究评估了6项单项测试,4项研究调查了2个测试群.只有一个测试，对趋同组和已知组进行了评估.显示足够收敛或已知群体有效性的测试的QoE(非常)低，而对于已知组有效性不足的单一测试或测试集群，QoE适中。
结论：所有临床评估的具有足够收敛或已知组有效性的腰骨盆SMC测试的QoE（非常低）低。因此,应谨慎解释试验结果,目前不建议在临床决策中高度依赖这些结果.
目的：根据COSMIN指南，评估LBP患者临床评估的LumbopelvicSMC测试的收敛和已知组有效性。
方法：系统评价方法：搜索了5个电子数据库，直到2023年12月。包括通过检查或触诊评估的LBP患者腰骨盆SMC测试的收敛或已知组有效性的研究。必须在LBP患者和无痛人群之间评估已知组的有效性。两名独立研究人员使用COSMIN偏见风险清单和修改后的分级方法评估了偏见和证据质量（QoE）的风险。分别。对于单个测试和测试集群，分别报告了已知组有效性的结果。
结果：纳入12项研究（946名参与者）。三项研究调查了三个单一测试的收敛效度。关于已知群体的有效性，6项研究评估了6项单项测试,4项研究调查了2个测试群.只有一个测试，对趋同组和已知组进行了评估.显示足够收敛或已知群体有效性的测试的QoE(非常)低，而对于已知组有效性不足的单一测试或测试集群，QoE适中。
结论：所有临床评估的具有足够收敛或已知组有效性的腰骨盆SMC测试的QoE（非常低）低。因此,应谨慎解释试验结果,目前不建议在临床决策中高度依赖这些结果.
